Physician profile
Shamsuddin Shaik
NPI 1518271154
$1,461.14
in general payments reported to CMS, 2019-2025
18 companies · $79.17 in 2025
The $79.17 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $446 · 2021: $17.11 · 2022: $123 · 2023: $131 · 2024: $143 · 2025: $79.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $353.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.56 | 2019-2020 | |
| Amgen INC. | $193.28 | 2019 | |
| Novo Nordisk INC | $145.79 | 2020-2023 | Sogroya |
| Esperion Therapeutics, INC. | $125.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $118.88 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $106.64 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $95.13 | 2024 | Strensiq |
| Astrazeneca Pharmaceuticals LP | $87.88 | 2019-2020 | |
| Madrigal Pharmaceuticals | $79.17 | 2025 | Rezdiffra |
| Abbott Laboratories | $78.66 | 2019-2023 | Freestyle Libre 3 |
| Corcept Therapeutics | $59.99 | 2020 | |
| Dexcom, INC. | $47.88 | 2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $26.28 | 2019 | |
| Medtronic, INC. | $24.18 | 2023 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $21.28 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amryt Pharma Holdings LTD | $18.47 | 2023 | Mycapssa |
| Merck Sharp & Dohme LLC | $13.23 | 2019 | |
| Shire North American Group INC | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shamsuddin Shaik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.